<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281059</url>
  </required_header>
  <id_info>
    <org_study_id>0429-10-HMO-CTIL</org_study_id>
    <nct_id>NCT01281059</nct_id>
  </id_info>
  <brief_title>Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Exalenz clinical investigation is a multicenter, non-randomized, blinded, study of the&#xD;
      ¹³C-Octanaote breath test (OBT). The OBT is a non-invasive test for evaluation of disease&#xD;
      severity in patients with suspected non alcoholic fatty liver disease (NAFLD) The purpose of&#xD;
      the study is to demonstrate that the ¹³C-Octanaote Breath Test (OBT) can be used as an aid,&#xD;
      in conjunction with other clinical information and medical history, for evaluating disease&#xD;
      severity and detecting non alcoholic steatohepatitis(NASH) with a high probability.&#xD;
&#xD;
      Retrospective analysis based on multivariable analysis will determined if and which&#xD;
      demographic, clinical and biochemical or imaging techniques data can assist in addition to&#xD;
      the data derived from OBT in differentiation of NASH, NAFL and possibly normals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>NAFLD</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BreathID - Breath Test - 13C Octanoate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men or women (&gt;18 years of age)&#xD;
&#xD;
          -  Liver -biopsy ( at least 1.7 cm and 4 portal tracts) performed within 6 months of&#xD;
             breath test or planned within the next 6 weeks, providing no treatment for liver&#xD;
             disease was given between the biopsy and the OBT Any elevation of liver enzymes above&#xD;
             the upper limit of normal (any or all of the following: AST,ALT, GGT, Alkaline&#xD;
             phosphatase)&#xD;
&#xD;
          -  At least one of the features of the metabolic syndrome&#xD;
&#xD;
               -  waist circumference &gt; 100 cm for men, 88 cm for women&#xD;
&#xD;
               -  triglycerides &gt; 150 mg/dl&#xD;
&#xD;
               -  fasting blood sugar &gt; 110 mg/dl&#xD;
&#xD;
               -  HDL cholesterol &lt; 40 mg/dl&#xD;
&#xD;
               -  blood pressure &gt; 130/85 mm Hg&#xD;
&#xD;
          -  No other known co-existent liver disease, excluded by appropriate serologic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive studies for any of the following:&#xD;
&#xD;
          -  hepatitis C (PCR)&#xD;
&#xD;
          -  hepatitis B (surface antigen or DNA)&#xD;
&#xD;
          -  iron saturation &gt; 60% + gene test for hereditary hemochromatosis&#xD;
&#xD;
          -  antinuclear antibody at a titer &gt; 1: 160 along with hypergammaglobulinemia and ALT&#xD;
             levels&gt;250 U/L&#xD;
&#xD;
               -  Patient has Alpha-1-antitrypsin level below lower limit of normal (&lt; 150 mg/dl)&#xD;
&#xD;
               -  Patient has alcohol consumption &gt; 20 gm/day for women and &gt; 30 gm/day for men&#xD;
&#xD;
               -  Patient is pregnant&#xD;
&#xD;
               -  Patient has been taking known hepatotoxic drugs e.g. (e.g.acebutolol,&#xD;
                  indomethacin,phenylbutazone,allopurinol,isoniazid,phenytoin,atenolol,ketoconazole&#xD;
                  ,piroxicam,carbamazepine,labetalol,probenecid,cimetidine,maprotiline,pyrazinamide&#xD;
                  ,dantrolene, metoprolol,quinidine,diclofenac, mianserin)• Patients that have had&#xD;
                  more than 10% reduction in body weight since biopsy&#xD;
&#xD;
               -  Patient with known severe congestive heart failure (LVEF on echocardiogram &lt; 20%)&#xD;
&#xD;
               -  Patient with known severe pulmonary hypertension (By echocardiogram, PAS &gt;45&#xD;
                  mmHg)&#xD;
&#xD;
               -  Patient with uncontrolled diabetes mellitus (HA1c&gt;10)&#xD;
&#xD;
               -  Patient with previous surgical bypass surgery&#xD;
&#xD;
               -  Patient with extensive short bowel syndrome(&gt;100 cm)&#xD;
&#xD;
               -  Patient currently receiving total parenteral nutrition&#xD;
&#xD;
               -  Patient is a recipients of any organ transplant&#xD;
&#xD;
               -  Patients that received any anti-viral treatment or any other liver therapy&#xD;
                  between the time of the biopsy and the breath test.&#xD;
&#xD;
               -  Women who are pregnant&#xD;
&#xD;
               -  Patients with an acute current exacerbation of chronic obstructive pulmonary&#xD;
                  disease or bronchial asthma.&#xD;
&#xD;
               -  Patient has taken drugs that can interfere with octanoate metabolism or can also&#xD;
                  cause NAFLD independent of the metabolic syndrome, including: corticosteroids,&#xD;
                  amiodarone, tetracycline, valproic acid, methotrexate, stavudine, zidovudine.&#xD;
&#xD;
               -  Patients unable or refuse to sign informed consent&#xD;
&#xD;
               -  Patients that based on the opinion of the investigator should not be enrolled&#xD;
                  into this study&#xD;
&#xD;
               -  Patients that are participating in other clinical trials evaluating experimental&#xD;
                  treatments or procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2012</last_update_posted>
  <responsible_party>
    <name_title>Gadi Lalazar</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

